ESPE Abstracts (2016) 86 P-P1-824

Syndromes: Mechanisms and Management P1

Growth Hormone Deficiency in Noonan Syndrome: Does it Influence Clinical Response to GH Therapy?

Maria Chiara Pellegrina, Gianluca Torneseb, Elena Faleschinib, Nicoletta Maserac, Gabriella Pozzobond, Angelo Selicornic & Alessandro Venturaa,b


aUniversity of Trieste, Trieste, Italy; bInstitute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy; cUniversity of Milano-Bicocca, MBBM Foundation, Monza, Italy; dSan Raffaele Scientific Institute, Vita-Salute University, Milano, Italy

Background: Short stature is a main feature of Noonan syndrome (NS). Although rhGH is commonly used in NS patients, it is not known whether a defect in the secretion of GH influences the response to rhGH therapy.

Objective and hypotheses: The aim of this study was to evaluate the efficacy and safety of rhGH treatment in NS patients, according to the presence of GH deficiency at the baseline.

Method: We retrospectively collected data of 34 patients with NS (18 males, mean age 9.1±3.4 years, 28 of 34 prepubertal). Genetic test was positive in 27 cases (24 with PTPN11 mutation). Before starting treatment with rhGH, at an average dose of 0.031±0.005 mg/kg per day, patients undertook GH secretion test after stimulation. With normal secretion test (peak >8 ng/ml), rhGH was administered off-label. Growth was evaluated as change in height Z-score (Delta-Height-SDS) at one, two and three years after the start of therapy.

Results: At the baseline 13 patients had a deficiency of GH secretion (Def group: 7.9±3.3 years; mean height −3.06±1.00 SDS, mean GH peak 5.4±1.3 ng/ml), while 21 showed no failure (NoDef group: 9.7±3.2 years; −2.95±0.81 SDS, 10±2 ng/ml). After 1 year, therapy with rhGH was effective in improving linear growth in both groups (Delta-Height-SDS Def 0.53±0.40, P<0.001; NoDef 0.32±0.31, P<0.001). Between the two groups we found no significant difference in growth at 1, 2 and 3 years from baseline, although a tendency was present at the second year (Delta-Height-SDS Def 0.90±0.53; NoDef 0.53±0.49, P=0.06). As side effects, insulin resistance (HOMA-IR>2.5) was reported in 5 subjects (Def: 3, 23.1%; NoDef: 2, 9.5%).

Conclusion: Therapy with rhGH significantly increases growth in patients with Noonan syndrome, regardless of the initial presence of a GH deficiency and in the absence of significant side effects even in subjects with normal stimulation test.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.